The invention relates to at least one probiotic strain of Lactobacillus plantarum for use in the treatment and/or prevention of age-related systemic inflammation in a human.

The invention relates to 5-({6-amino-2-[4-(5-chloro-2-cyanophenyl)-5-methoxy-2-oxopyridin-1(2H)-yl]-3-methylhexanoyl}amino)pyrazolo[1,5-a]pyridine-3-carboxamide, to processes for its preparation, to its use for the treatment and/or prophylaxis of diseases and to its use for the preparation of medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and edemas, and also ophthalmic disorders, and its use to inhibit disturbing plasma kallikrein activity for the conduct of extracorporeal procedures and analytical assays.

An oral disintegrating tablet (ODT) comprising an active ingredient, about 1 to about 20% w/w of at least one amphiphilic compound, about 1 to about 60% w/w of at least one disintegrant and about 0.5 to about 5% w/w of at least one binder, wherein the ODT has hardness of at least about 1 kp and wherein, when the ODT contacts a hydrophilic solvent, the amphiphilic compound self-assembles into liquid crystalline particles.

An oral disintegrating tablet that forms liquid crystalline particles or liquid crystalline bulk phase upon disintegration. The oral disintegrating tablet is fast disintegrating following contact with saliva and/or the oral mucosa but also provides slowed delivery of the active ingredient to avoid the difficulties associated with the speed of delivery of an active ingredient through the oral mucosa.

An HS-25 tablet, an HS-25 solid dispersion composition, a preparation method therefor and usage thereof. The HS-25 tablet is made by using HS-25 and excipients for wet granulation, drying, granulating and tablet pressing.

Provided is a granulation composition that comprises core grains, coating grains and a binder for binding the core grains to each other and also binding the core grains to the coating grains to thereby maintain a granular shape, characterized in that: the coating grains adhere around a main granulation body comprising the core grains and the binder; the coating grains are insoluble in the binder; the core grains and/or the binder contain a medicinal ingredient or a biofunctional ingredient; and the developed interfacial area ratio Sdr is 100-700. According to this granulation composition, a uniform granulated product which is surface-coated with the coating grains and hardly segregated can be stably obtained, even if using a dilute solution with low gel strength as the binder. By setting the gelling agent concentration in the binder at a low level to give a dilute solution, therefore, the granulation composition having excellent properties can be produced at a high productivity.

Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered. This distinct response can comprise changes in levels of one or more markers in the individual and/or co-localization of IL-10 in the lamina propria of the individual. Further described herein, in some embodiments, are oral formulations of the cholix-IL-10 fusion proteins. Described herein are methods for the purification of an IL-10 delivery construct, including methods for refolding and enrichment, which can result in maintenance of a high percentage of the IL-10 delivery constructs in the biologically active dimer form. Described herein are oral formulations configured for site-specific release of a therapeutic protein in the small intestines or colon. In some cases, the therapeutic protein is in the form of a dimer, such as an IL-10 delivery construct capable of crossing the gut epithelium.

Disclosed herein are the sublingual pharmaceutical compositions comprising remdesivir or its pharmaceutically acceptable salts or solvates thereof. The present invention also relates to a process for preparing sublingual pharmaceutical compositions comprising remdesivir or its pharmaceutically acceptable salts or solvates thereof. Compositions of remdesivir prepared as per present invention are able to increase bioavailability by avoiding first-pass metabolism. The compositions of remdesivir prepared as per present invention are useful in the treatment of viral infections including coronavirus infection (COVID-19). The compositions of remdesivir prepared as per present invention exhibit desired pharmaceutical technical attributes such as pH, assay, related substance, disintegration and dissolution.

The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients having mild or moderate hepatic impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.